C₂N Diagnostics, LLC Announces Investment From Eisai Inc.
C₂N Diagnostics, LLC , a leader in advanced brain health diagnostics, and Eisai Inc. , a “human health care company,” have announced Eisai has made an investment of up to 15 million USD in C₂N.
- C₂N Diagnostics, LLC , a leader in advanced brain health diagnostics, and Eisai Inc. , a “human health care company,” have announced Eisai has made an investment of up to 15 million USD in C₂N.
- C₂N executives say the investment reflects the two companies’ shared desire to scale up and provide broad access to its Precivity™ tests , which are innovative blood tests intended for use in patients with cognitive impairment.
- These tests aim to help healthcare providers determine Alzheimer’s disease pathology, and aid in medical management and treatment decisions.
- “Given the expense and capacity limitations of PET and CSF tests, Eisai is working to support the dementia ecosystem’s growth.